Details of the Drug

General Information of Drug (ID: DMY67U8)

Drug Name
Trapidil
Synonyms
trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991
Indication
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Phase 4 [1]
Coronary artery disease BA80 Phase 4 [1]
Multiple myeloma 2A83 Investigative [2]
Affected Organisms
Humans and other mammals
ATC Code
C01DX11: Trapidil
C01DX: Other vasodilators used in cardiac diseases
C01D: VASODILATORS USED IN CARDIAC DISEASES
C01: CARDIAC THERAPY
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 205.26
Logarithm of the Partition Coefficient (xlogp) 1.7
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h [3]
Bioavailability
96% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The clearance of drug is 179 mL/min for a single dose [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.31 hours [3]
Chemical Identifiers
Formula
C10H15N5
IUPAC Name
N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
Canonical SMILES
CCN(CC)C1=CC(=NC2=NC=NN12)C
InChI
InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
InChIKey
GSNOZLZNQMLSKJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5531
ChEBI ID
CHEMBL132767
CAS Number
15421-84-8
UNII
EYG5Y6355E
DrugBank ID
DB09283
TTD ID
D0U2CV
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 3 (FGFR3) TTST7KB FGFR3_HUMAN Inhibitor [2]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute coronary syndrome
ICD Disease Classification BA41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor receptor 3 (FGFR3) DTT FGFR3 8.57E-01 0.02 0.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00914420) Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide Stent Versus Taxus . U.S. National Institutes of Health.
2 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
3 Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis. Br J Clin Pharmacol. 1996 Oct;42(4):443-9.
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.